

Literaturübersicht: Medizinalcannabis gegen Spastik bei MS

Stand: 21.12.2021, SGCM-SSCM

Allan GM et al. Systematic review of systematic reviews for medical cannabinoids: Pain, nausea and vomiting, spasticity, and harms. *Can Fam Physician* 2018; 64(2): e78-e94.

Blake DR, Robson P, Ho M, Jubb RW, McCabe CS. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. *Rheumatology* 2006; 45(1): 50-2.

Collin C, Davies P, Mutiboko I, Ratcliffe S, Group SSiMS. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. *Eur J Neurol* 2007; 14(3): 290-6.

Collin C et al. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. *Neurol Res* 2010; 32(5): 451-9.

Corey-Bloom J et al. Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial. *CMAJ* 2012; 184(10): 1143-50.

Leocani L et al. Sativex® and clinical- neurophysiological measures of spasticity in progressive multiple sclerosis. *J Neurol* 2015; 262(11): 2520-7.

Markovà J et al. Sativex® as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial. *Int J Neurosci* 2019; 129(2): 119-28.

Novotna A et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols*(Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. *Eur J Neurol* 2011; 18(9): 1122-31.

Russo M, Naro A, Leo NA, Sessa E, D'Aleo G, Bramanti P, Calabrò RS. Evaluating Sativex® Neuropathic Pain Management: A Clinical and Neurophysiological Assessment in Multiple Sclerosis. *Pain Med* 2016; 17: 1145-1154.

Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. *BMJ* 2004; 329(7460): 253.

Torres-Moreno MC, Papaseit E, Torrens M, Farré M. Assessment of Efficacy and Tolerability of Medicinal Cannabinoids in Patients With Multiple Sclerosis: A Systematic Review and Meta-analysis. *JAMA Netw Open* 2018; 1: 1-16.

Van Amerongen G et al. Effects on spasticity and neuropathic pain of an oral formulation of Δ9-tetrahydrocannabinol in patients with progressive multiple sclerosis. *Clin Ther* 2018; 40(9): 1467-82.

Vaney C et al. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. *Mult Scler* 2004; 10(4): 417-24.

Wade DT, Collin C, Stott C, Duncombe P. Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. *Mult Scler* 2010; 16: 707-14.

Wade DT, Makela P, Robson P, House H, Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo- controlled study on 160 patients. *Mult Scler* 2004; 10(4): 434-41.

Wade DT, Robson P, House H, Makela P, Aram J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. *Clin Rehab* 2003; 17(1): 21-9.

Whiting PF et al. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. *JAMA* 2015;313(24): 2456-73.

Zajicek J et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. *Lancet* 2003; 362(9395): 1517-26.

Zajicek JP et al. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. *JNeurol NeurosurgPsychiatry* 2005; 76(12): 1664-9.

Zettl UK, Rommer P, Hipp P, Patejdl R. Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis. *Ther Adv Neurol Disord* 2016; 9: 9-30.